Scholar Rock Holding logo

Scholar Rock HoldingNASDAQ: SRRK

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

25 May 2018

Next earnings report:

07 November 2024

Last dividends:

N/A

Next dividends:

N/A
$2.31 B
-15%vs. 3y high
82%vs. sector
-vs. 3y high
-vs. sector
-15%vs. 3y high
96%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 23:13:54 GMT
$28.91-$0.64(-2.17%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

SRRK Latest News

Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
businesswire.com01 November 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024, at 8:15am ET. To access the live conf.

Should You Buy Scholar Rock Holding Corporation (SRRK) After Golden Cross?
zacks.com21 October 2024 Sentiment: POSITIVE

Scholar Rock Holding Corporation (SRRK) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, SRRK's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

Here's Why Everybody's Talking About Scholar Rock Right Now
fool.com09 October 2024 Sentiment: POSITIVE

Successful clinical-trial results recently made Scholar Rock one of the stock market's top performers.

Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants
businesswire.com08 October 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the pricing of an upsized underwritten public offering of 10,265,488 shares of its common stock at a public offering price of $28.25 per share and, in lieu of common stock to.

SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal
zacks.com08 October 2024 Sentiment: POSITIVE

Scholar Rock stock skyrockets as the late-stage study of the investigational therapy, apitegromab, to treat spinal muscular atrophy meets the primary goal.

Scholar Rock (SRRK) Shares Surge on Successful SMA Drug Trial
gurufocus.com07 October 2024 Sentiment: POSITIVE

Shares of Scholar Rock Holding Corp. (SRRK, Financial) soared by 335% as their candidate drug for spinal muscular atrophy (SMA), apitegromab, achieved the primary endpoint in a Phase 3 trial. The positive results indicate that the apitegromab monoclonal antibody significantly improves motor function in patients.

Scholar Rock: SMA Program Strides Forward With Positive Clinical Data
seekingalpha.com07 October 2024 Sentiment: POSITIVE

Apitegromab met the primary endpoint in its phase 3 SAPPHIRE study for spinal muscular atrophy, setting up BLA & MAA filings in Q1 2025. Apitegromab is the first treatment targeting muscle fiber atrophy in SMA, potentially changing the standard of care and offering a competitive edge. Scholar Rock also has apitegromab being explored in a phase 2 study for obesity, with clinical data expected in Q2 2025, presenting another catalyst.

Scholar Rock to Participate in Upcoming Investor Conferences
businesswire.com29 August 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference: Scholar Rock is scheduled to participate in.

Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting
businesswire.com03 June 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced encouraging data from its Phase 1 DRAGON proof-of-concept trial of SRK-181, a selective inhibitor of latent TGFβ1 activation, in combination with pembrolizumab in patients with advanced solid tu.

Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
businesswire.com28 May 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced it will present new data from its Phase 1 DRAGON proof-of-concept trial of SRK-181 in combination with pembrolizumab in patients with advanced solid tumors in an oral presentation during the Ame.

What type of business is Scholar Rock Holding?

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

What sector is Scholar Rock Holding in?

Scholar Rock Holding is in the Healthcare sector

What industry is Scholar Rock Holding in?

Scholar Rock Holding is in the Biotechnology industry

What country is Scholar Rock Holding from?

Scholar Rock Holding is headquartered in United States

When did Scholar Rock Holding go public?

Scholar Rock Holding initial public offering (IPO) was on 25 May 2018

What is Scholar Rock Holding website?

https://scholarrock.com

Is Scholar Rock Holding in the S&P 500?

No, Scholar Rock Holding is not included in the S&P 500 index

Is Scholar Rock Holding in the NASDAQ 100?

No, Scholar Rock Holding is not included in the NASDAQ 100 index

Is Scholar Rock Holding in the Dow Jones?

No, Scholar Rock Holding is not included in the Dow Jones index

When was Scholar Rock Holding the previous earnings report?

No data

When does Scholar Rock Holding earnings report?

The next expected earnings date for Scholar Rock Holding is 07 November 2024